Overview

Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections

Status:
Unknown status
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate a new medication dosed once a week in the treatment of bacterial infections in the blood from intravenous catheters (CR-BSI). The primary objective is to evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI relative to a standard of care treatment, vancomycin.
Phase:
Phase 2
Details
Lead Sponsor:
Vicuron Pharmaceuticals
Treatments:
Dalbavancin
Teicoplanin
Vancomycin